Q: Could you please comment on last week's NR from DHT.UN (see below). The market responded favourably and so did the analysts with a multitude of raised targets. Thanks as always.
Immediate and accretive cash flow generation replaces structured annual caps –
– Increasing capital deployment guidance to over US$1.25 billion deployed for the five years ending 2025 –
– Now expecting high-teens Royalty Income CAGR through 2025 and mid- to high-single digit Royalty Income CAGR through 2030, excluding any new transactions –
this is the press release we are referencing.
https://drihealthcare.com/dri-healthcare-trust-announces-the-expansion-of-its-royalty-entitlement-on-the-us-net-sales-of-omidria-updates-deployment-and-cagr-guidance/
Immediate and accretive cash flow generation replaces structured annual caps –
– Increasing capital deployment guidance to over US$1.25 billion deployed for the five years ending 2025 –
– Now expecting high-teens Royalty Income CAGR through 2025 and mid- to high-single digit Royalty Income CAGR through 2030, excluding any new transactions –
this is the press release we are referencing.
https://drihealthcare.com/dri-healthcare-trust-announces-the-expansion-of-its-royalty-entitlement-on-the-us-net-sales-of-omidria-updates-deployment-and-cagr-guidance/
5i Research Answer:
Note we have posted other comments on the company today. The guidance and expansion are solid developments. Much of course will depend on what the company does with its spending, but the increased allocation is also positive.